Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.
Saved in:
| Title: | Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors. |
|---|---|
| Authors: | Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Hong JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Park JO; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Lee SY; ImmuneOncia Therapeutics Inc., Seoul, Korea., Kim S; ImmuneOncia Therapeutics Inc., Seoul, Korea., Yun HY; College of Pharmacy, Chungnam National University, Daejeon, Korea., Ock CY; Lunit Inc., Seoul, Korea., Hwang W; Lunit Inc., Seoul, Korea., Kim SH; ImmuneOncia Therapeutics Inc., Seoul, Korea., Kim HT; ImmuneOncia Therapeutics Inc., Seoul, Korea., Lim HY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. |
| Source: | Cancer research and treatment [Cancer Res Treat] 2025 Nov 04. Date of Electronic Publication: 2025 Nov 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
